Immune-Onc Therapeutics Overview
- Founded
-
2016

- Status
-
Private
- Employees
-
39

- Latest Deal Type
-
Series B3
- Latest Deal Amount
-
$25M
- Investors
-
21
Immune-Onc Therapeutics General Information
Description
Operator of a clinical-stage cancer immunotherapy company intended to translate unique scientific insights into myeloid cell biology and immune inhibitory receptors. The company has a focused platform approach and differentiated pipeline and has developed first-in-class biotherapeutics that disarm immune suppression in the tumor microenvironment, enabling patients to have access to new immunomodulatory.
Contact Information
Website
www.immune-onc.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 795 San Antonio Road
- Palo Alto, CA 94303
- United States
+1 (650) 000-0000
Immune-Onc Therapeutics Timeline
Immune-Onc Therapeutics Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
9. Later Stage VC (Series B3) | 05-Jan-2023 | $25M | 00000 | 00000 | Completed | Clinical Trials - Phase 1 |
8. Grant | 20-Apr-2021 | 000 | 00000 | Completed | Clinical Trials - Phase 1 | |
7. Later Stage VC (Series B1) | 30-Mar-2021 | 000.00 | 00000 | 00000 | Completed | Clinical Trials - General |
6. Grant | 04-Aug-2020 | 00.000 | 000.00 | Completed | Pre-Clinical Trials | |
5. Grant | 01-Aug-2020 | 00.000 | 000.00 | Completed | Pre-Clinical Trials | |
4. Debt - PPP | 13-Apr-2020 | 000.00 | Completed | Pre-Clinical Trials | ||
3. Early Stage VC (Series B) | 18-Sep-2018 | 0000 | 000.00 | 000.00 | Completed | Pre-Clinical Trials |
2. Accelerator/Incubator | 28-Jun-2017 | $500K | $7.5M | Completed | Product Development | |
1. Early Stage VC (Series A) | 01-Sep-2016 | $7M | $7M | 0000 | Completed | Product Development |
Immune-Onc Therapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series B3 | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 0.00 |
Series B2 | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 0.000 |
Series B1 | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Series B | 20,988,105 | $0.000100 | 6% | $1.58 | $1.58 | 1x | $1.58 | 17.37% |
Series A | 8,634,934 | $0.000100 | 6% | $0.81 | $0.81 | 1x | $0.81 | 7.15% |
Immune-Onc Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Operator of a clinical-stage cancer immunotherapy company intended to translate unique scientific insights into myeloid
Drug Discovery
Palo Alto, CA
39
As of 2023
00000
0000
0000-00-00
00000000000
00000
Immune-Onc Therapeutics Competitors (36)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Pionyr Immunotherapeutics | Venture Capital-Backed | South San Francisco, CA | 00 | 00000 | 000000 - 000 | 00000 |
000000 00000000000 | Venture Capital-Backed | South San Francisco, CA | 00 | 00000 | 0000000000 0 | 00000 |
00000 000000000 | Venture Capital-Backed | Nahariya, Israel | 00 | 000.00 | 00000000000 | 000.00 |
000000000000 | Venture Capital-Backed | Seattle, WA | 00 | 00000 | 000000000 | 00000 |
000 00000000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 000000000 | 00000 |
Immune-Onc Therapeutics Patents
Immune-Onc Therapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2021236302-A1 | Novel anti-lilrb4 antibodies and derivative products | Pending | 12-Mar-2020 | 00000000000 | |
CA-3175140-A1 | Novel anti-lilrb4 antibodies and derivative products | Pending | 12-Mar-2020 | 00000000000 | |
EP-4118120-A2 | Novel anti-lilrb4 antibodies and derivative products | Pending | 12-Mar-2020 | C07K16/2803 |
Immune-Onc Therapeutics Executive Team (8)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Charlene Liao Ph.D | Co-Founder, Chief Executive Officer, President & Chairman | ||
Christopher Whitmore | Chief Financial Officer | ||
Guoliang Yu Ph.D | Co-Founder & Board Member | ||
Chengcheng Zhang Ph.D | Scientific Founder | ||
Paul Woodard MD | Chief Medical Officer |
Immune-Onc Therapeutics Board Members (10)
Name | Representing | Role | Since |
---|---|---|---|
Austin Gurney Ph.D | Immune-Onc Therapeutics | Board Member | 000 0000 |
Barbara Klencke MD | Self | Board Member | 000 0000 |
Bing Yao | Immune-Onc Therapeutics | Board Member | 000 0000 |
Charlene Liao Ph.D | Immune-Onc Therapeutics | Co-Founder, Chief Executive Officer, President & Chairman | 000 0000 |
Dave Chenn | Oceanpine Capital | Board Member | 000 0000 |
Immune-Onc Therapeutics Signals
Immune-Onc Therapeutics Investors (21)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Proxima Ventures (China) | Venture Capital | Minority | 000 0000 | 000000 0 | |
Triwise Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
Wuxi Biologics | Corporation | Minority | 000 0000 | 000000 0 | |
Leukemia & Lymphoma Society | Not-For-Profit Venture Capital | Minority | 000 0000 | 000000 0 | |
Oceanpine Capital | Venture Capital | Minority | 000 0000 | 000000 0 |